|
Studienakronym |
Krankheitsentität  |
Vollständiger Titel / Beschreibung |
Status |
|
|
AIO-KRK-0117 / Elderly |
Tumor des Dickdarms / Mastdarms
[]
|
Aflibercept and 5-FU vs. FOLFOX as 1st line treatment for elderly or frail elderly patients with metastatic colorectal cancer
|
 |
 |
|
|
AIO-KRK-0216 - AVETUX |
Tumor des Dickdarms / Mastdarms
[]
|
ENDE DER REKRUTIERUNG!!!
Avelumab and cetuximab in combination with FOLFOX in patients with previously untreated metastatic colorectal cancer – The phase II AVETUX-CRC Trial
|
 |
|
|
AIO-NET-0112 / EVINEC |
Neuroendokrine Tumore (NET)
[C15-C26, D13]
|
Safety and Tolerability of Everolimus as second-line Treatment on poorly differentiated neuroendocrine carcinoma/ neuroendocrine carcinoma G3 according to WHO 2010 and neuroendocrine Tumor G3 - an investigator initiated Phase II study
|
|
|
|
|
AIO-PAK 0116 PANTHEON |
Bauchspeicheldrüsenkrebs (Pankreas)
[]
|
A health service research study to investigate survival of metastatic pancreatic cancer patients after sequential chemotherapy: An AIO phase II cross over trial
|
|
|
|
|
AIO-PAK-0113 NEOLAP |
Krankheit des Pankreas, nicht näher bezeichnet
[K86.9]
|
Prospective randomized multicenter phase II trial to investigate intensified neoadjuvant chemotherapy in locally advanced pancreatic cancer
|
|
|
|
|
AIO-PAK-0114 ALPACA |
Bauchspeicheldrüsenkrebs (Pankreas)
[]
|
Induction treatment with nab-paclitaxel/gemcitabine for first-line treatment of metastatic pancreatic cancer followed by either alternating application of gemcitabine monotherapy and nab-paclitaxel/gemcitabine or continuing application of nab-paclitaxel/gemcitabine: A randomized phase II study
|
|
|
|
|
AIO-PAK-0313 NEONAX |
Bauchspeicheldrüsenkrebs (Pankreas)
[]
|
Neoadjuvante plus adjuvante oder nur adjuvante Therapie mit nab?
Paclitacel plus Gemcitabine bei resektablem Bauchspeicheldrüsenkrebs ?
eine prospektive, randomisierte, kontrollierte Phase II Studie der AIO
Arbeitsgruppe Pankreaskarzinom
|
|
|
|
|
AIO-STO 0114 S-1 Adjuvant |
Magentumor
[]
|
Multicenter Phase I/II Feasibility Study of Adjuvant Treatment with S-1 in Patients after R0-Resection of Adenocarcinoma of the Stomach and Esophagogastric Junction
|
|
|
|
|
AIO-STO 0209 SUN-CASE |
Magentumor
[]
|
randomized, placebo-controlled phase II trial investigation sunitinib versus placebo in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus treated with chemotherapy FOLFIRI
|
|
|
|
|
AIO-STO-0217 - INTEGA |
Speiseröhrenkrebs
[]
|
Ipilimumab in Kombination mit Nivolumab und Trastuzumab bei bisher unbehandelten HER2 positiven Patienten mit lokal fortgeschrittenem oder metastasiertem EsophagoGastric Adenokarzinom
Die randomisierte Phase 2 INTEGA Studie.
|
|
|
|
|
AIO-STO-0417 (Moonlight) |
Magentumor
[]
|
Modified FOLFOX plus/minus Nivolumab and Ipilimumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction –
A randomized phase 2 Trial
|
|
|
|
|
AIO-YMO-0111 (MATEO) |
Speiseröhrenkrebs
[]
|
Randomized controlled trial of S-1 maintenance therapy in metastatic esophagogastric carcinoma MATEO (maintenance Teysuno in esophagogastric carcinoma)
|
|
|
|
|
AKRENDO |
Endometriose, nicht näher bezeichnet
[N80.9]
|
A randomized, placebo-controlled, double-blind, parallel-group, multi-center,
exploratory dose-response study to assess the efficacy and safety of different oral doses
of BAY 1128688 in women with symptomatic endometriosis over a 12-week Treatment period
Exploratory dose-response study in endometriosis patients
|
|
|
|
|
ALL Register |
Akute lymphatische Leukämie [ALL]
[C91.0-]
Blutkrebs (z.B. Leukämie, Lymphome)
[]
|
GMALL-Register und Biomaterialbank
Biomaterialsammlung und prospektive Datenerfassung zu Diagnostik, Behandlung und Krankheitsverlauf der ALL des Erwachsenen
(akute lymphatische Leukämie, ALL, Leukämie, Blutkrebs, weiße Blutkörperchen, Blut, blutbildendes System, Leukozyten, Lymphoblasten)
|
|
|
|
|
ALL SCT ped 2012 FORUM |
Sonstige Studien
[-]
|
Allogeneic Stem Cell Transplantation in Children and Adolescents with Acute Lymphoblastic Leukaemia
|
|
|
|
|
ALPACA |
Bösartige Neubildung des Pankreas
[C25.-]
Bauchspeicheldrüsenkrebs (Pankreas)
[]
|
Induction treatment with nab-paclitaxel/gemcitabine for first-line treatment of metastatic pancreatic cancer followed by either alternating application of gemcitabine monotherapy and nab-paclitaxel/gemcitabine or continuing application of nab-paclitaxel/gemcitabine: A randomized phase II study
|
|
|
|
|
Alpha-RT |
Bösartige Neubildung der Prostata
[C61]
Prostatakrebs
[]
|
Phase II open-label study to evaluate the efficacy and safety of Radium-223 dichloride in combination with external beam radiotherapy (EBRT) vs. external beam radiotherapy alone in the treatment of advanced castration resistant prostate carcinoma with limited bone metastases
|
 |
|
|
|
Alpharadin BAY 88-8223 |
Prostatakrebs
[]
|
Radium(223) Dichloride (Alpharadin) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases
|
|
|
|
|
ALPS |
Ductus pancreaticus
[C25.3]
Bauchspeicheldrüsenkrebs (Pankreas)
[]
|
A Phase Ib and II Open-Label, Multi-Center Study of MEDI4736 Evaluated as Single Agent or in Different Combinations in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
|
|
|
|
|
ALTERNATIVE |
Follikuläres Lymphom, nicht näher bezeichnet
[C82.9]
Follikuläres Lymphom Grad I
[C82.0]
Follikuläres Lymphom Grad II
[C82.1]
Follikuläres Lymphom Grad III, nicht näher bezeichnet
[C82.2]
|
A prospective multicenter Phase 2 Study of the Chemotherapy-free Combination of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib) in Combination with Obinutuzumab (GA 101) in Patients with Previously Untreated Follicular Lymphoma (FL) and a High Tumor Burden
|
|
|
|
|
Alternative |
Blutkrebs (z.B. Leukämie, Lymphome)
[]
|
A prospective multicenter Phase 2 Study of the Chemotherapy-free Comination of the Bruton´s Tyrosine Kinase Inhibitor,PCI-32765(Ibrutinib) in Combination with Obinutuzumab (GA101) in Patients with Previously Untreated Follicular Lymphoma (FL) and a High Tumor Burden
|
|
|
|
|
ALTERNATIVE-C |
Follikuläres Lymphom Grad I
[C82.0]
Follikuläres Lymphom Grad II
[C82.1]
Follikuläres Lymphom Grad IIIa
[C82.3]
|
A prospective Prospective multicenter Multicenter Phase 2 Study of the Chemotherapy-free Free Combination of the intravenous Intravenous Phosphatidylinositol-3-Kinase (PI3K) Inhibitor Copanlisib in Combination with Obinutuzumab in Patients with Previously Untreated Follicular Lymphoma (FL) and a High Tumor Burden
|
|
|
|
|
ALTTO ( GSK ) |
Brustkrebs
[]
|
Adjuvant Pivotal Trial of Herceptin or Lapatinib or Dual Inhibition of ErB2
|
|
|
|
|
AMBIGUARD |
Infektiologie
[-]
Lymphatische Leukämie
[C91.-]
Blutkrebs (z.B. Leukämie, Lymphome)
[]
|
GS-EU-131-0247 A Phase 3, Double-Blind, Multicenter, Randomized,Placebo-Controlled Study to Assess the Efficacy, Safety and Tolerability of Prophylactic Liposomal Amphotericin B (AmBisome®) for the Prevention of Invasive Fungal Infections (IFIs) in Subjects Receiving Remission-Induction Chemotherapy for Acute Lymphoblastic Leukemia (ALL)
|
|
|
|
|
AMG 199 - 20180290 |
Magentumor
[]
|
A Global Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of the Half-life Extended Bispecific T-cell Engager AMG 199 in Subjects with MUC17-Positive Gastric and Gastroesophageal Junction Cancer
|
|
|
